Pages that link to "Q32012802"
Jump to navigation
Jump to search
The following pages link to Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hy (Q32012802):
Displaying 10 items.
- A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy (Q24646209) (← links)
- Molecular mechanisms of hypoxia in cancer (Q33705108) (← links)
- Theory, instrumentation, and applications of electron paramagnetic resonance oximetry (Q33847052) (← links)
- Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer (Q33881902) (← links)
- Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy (Q34498046) (← links)
- Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia (Q36622759) (← links)
- In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography (Q36694230) (← links)
- Dual-function pH and oxygen phosphonated trityl probe (Q37682657) (← links)
- Synthesis and characterization of amino derivatives of persistent trityl radicals as dual function pH and oxygen paramagnetic probes (Q42184809) (← links)
- Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK. (Q43236564) (← links)